Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Conditions: Chronic Myeloid Leukemia; Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission; Chronic Myeloid Leukemia in Remission Interventions: Other: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal; Drug: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation Sponsor: Baylor College of Medicine Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Leukemia | Nilotinib | Research | Tasigna